Early Use of ctDNA May Accelerate Time to Treatment and Improve Survival in NSCLC

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

Related Keywords

New York ,United States ,Leslyem Heisler ,Charu Aggarwal ,University Of Pennsylvania ,Physician Education Resource ,Penn Center ,Annual New York Lung Cancers Symposium ,Associate Professor ,Lung Cancer Excellence ,Neck Medical Oncology ,Precision Oncology Innovation ,Cancer Care Innovation ,Molecular Data ,International Association ,Lung Cancer ,Hwangw T ,D ,Bph ,Pasco ,New York Lung Cancer Symposium ,Ctdna ,Circulating Tumor Dna ,